申请人:Dharmacon, Inc.
公开号:EP2261334A2
公开(公告)日:2010-12-15
Methods and compositions for performing RNA interference comprising a wide variety of stabilized siRNAs suitable for use in serum-containing media and for in vivo applications, such as therapeutic applications, are provided. These siRNAs permit effective and efficient applications of RNA interference to applications such as diagnostics and therapeutics through the use of one or more modifications including orthoesters, terminal conjugates, modified linkages and 2'-modified nucleotides. Uniquely modified siRNAs have been developed that reduce off-target effects incurred in gene-silencing. The modifications include: phosphorylation of the first 5' terminal antisense nucleotide; 2' carbon modifications of the first and second or first, second, and third 5' terminal antisense nucleotides; and optionally 2' carbon modifications of the first and second or first, second, and third 5' terminal sense nucleotide. Control and exaequo molecules are also provided. siRNA molecules and related control, trackability and exaequo agents with specific stability modifications were developed.
本发明提供了进行 RNA 干扰的方法和组合物,其中包括适合在含血清介质中使用和用于体内应用(如治疗应用)的各种稳定 siRNA。这些 siRNA 通过使用一种或多种修饰(包括正酯、末端共轭物、修饰连接和 2'- 修饰核苷酸),可将 RNA 干扰有效、高效地应用于诊断和治疗等领域。已开发出的独特修饰 siRNA 可减少基因沉默过程中产生的脱靶效应。这些修饰包括:第一个 5'末端反义核苷酸的磷酸化;第一个和第二个或第一个、第二个和第三个 5'末端反义核苷酸的 2'碳修饰;以及第一个和第二个或第一个、第二个和第三个 5'末端有义核苷酸的 2'碳修饰。此外,还提供了具有特定稳定性修饰的 siRNA 分子及相关的控制、可追踪性和 exaequo 剂。